What types of policy changes does Independence Blue Cross issue?

Independence Blue Cross regularly publishes coverage updates including prior authorization requirement changes, billing code additions or deletions, plan-type coverage modifications, and clinical policy revisions. PolicyChanges.app monitors these notices and summarizes the impact for providers.

How often does Independence Blue Cross update its policies?

Independence Blue Cross typically releases policy bulletins on a rolling basis throughout the year. Our system checks for new updates daily and adds them to this feed as soon as they are identified.

How many Independence Blue Cross policy changes are tracked here?

This page currently tracks 9 documented Independence Blue Cross policy changes. New items are added as they are identified.

What should I do when Independence Blue Cross changes a prior authorization policy?

Review each change's effective date and action-required notes. Update your billing and clinical workflows before the effective date to avoid claim denials. Each policy detail page on PolicyChanges.app includes a plain-English summary and action items.

Independence Blue Cross Policy Changes & Prior Auth Updates

We track 9 documented policy changes from Independence Blue Cross across PA. Each entry includes an AI-generated plain-English summary, effective date, affected billing codes, and a direct link to the original Independence Blue Cross notice. Use the related links below to narrow results by specialty or state, or sign up for a free daily alert to receive new Independence Blue Cross updates automatically.

Medium impact
Tildrakizumab-asmn (Ilumya®)
Independence Blue Cross·Effective Sep 14, 2026
Medicare Advantage policy for Tildrakizumab-asmn (Ilumya®) adds new requirement prohibiting concurrent therapy with other biologic DMARDs or JAK inhibitors for continuation therapy. All ICD-10 codes removed from policy, requiring providers to report appropriate diagnosis codes supporting medical necessity.
High impact
Multiple Surgery Payment Reduction
Independence Blue Cross·Effective Sep 1, 2026
Medicare Advantage plans will reduce reimbursement for multiple surgical procedures performed on the same date - third and subsequent surgeries will now be paid at only 35% of allowance (previously 50%). This affects all surgical specialties performing multiple procedures in one session.
Medium impact
Spinal Orthoses
Independence Blue Cross·Effective Aug 18, 2026
Face-to-Face encounter requirements have been removed for spinal orthoses codes L0457 and L4000, and new CG modifier requirements have been added for specific LSO/TLSO codes when made of nonelastic material or having rigid posterior panels. The policy becomes effective August 18, 2026.
Medium impact
Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Effective Aug 3, 2026
Medicare Advantage policy updates VEGF antagonist coverage for eye injections, adding ranibizumab-leyk (Nufymco) as covered and requiring at least 3 monthly injections to document inadequate response before moving to higher-tier products. The policy establishes a 3-tier preferred product system with bevacizumab as Level 1 preferred.
Medium impact
Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)
Independence Blue Cross·Effective Jun 29, 2026
Medicare Advantage policy for E&M of diabetic peripheral neuropathy with LOPS will be archived on June 29, 2026, as the service is now considered standard of care. The policy previously covered E&M services every 6 months for documented diabetic neuropathy with LOPS, but this specific coverage policy will no longer exist.
Medium impact
Tildrakizumab-asmn (Ilumya®)
Independence Blue Cross·Effective Sep 14, 2026
New policy for Tildrakizumab-asmn (Ilumya®) effective 09/14/2026 adds a requirement that patients cannot receive concurrent therapy with other biologic DMARDs or JAK inhibitors. All ICD-10 codes have been removed from the policy, requiring providers to report the most appropriate diagnosis codes based on medical necessity criteria.
High impact
Multiple Surgery Payment Reduction
Independence Blue Cross·Effective Sep 1, 2026
The insurance company is changing their multiple surgery payment reduction policy, decreasing reimbursement for third and subsequent surgical procedures from the previous rate to 35% of the provider's allowance when performed on the same date by the same provider. The payment hierarchy remains: first procedure 100%, second procedure 50%, third and subsequent procedures 35%.
High impact
Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Effective Aug 3, 2026
New policy establishes 3-tier preference system for VEGF eye injection drugs, requiring step therapy documentation and adding ranibizumab-leyk (Nufymco) as covered. Bevacizumab is preferred first-line, ranibizumab second-line, with all other drugs requiring failure of both preferred options.
Medium impact
Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)
Independence Blue Cross·Effective Jun 29, 2026
Policy for E&M of diabetic peripheral neuropathy with LOPS will be archived effective June 29, 2026, as the service is now considered standard of care. Codes G0245 and G0246 are not separately reimbursable when billed with E&M, consultation, or routine foot care codes.

Independence Blue Cross in PA Independence Blue Cross: Cardiothoracic Surgery Independence Blue Cross: Dermatology Independence Blue Cross: Endocrinology Independence Blue Cross: ENT (Ear, Nose & Throat)All payers

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Independence Blue Cross Policy Changes 2026 | Prior Auth & Coverage Updates | PolicyChanges.app

Tildrakizumab-asmn (Ilumya®)

Multiple Surgery Payment Reduction

Spinal Orthoses

Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors

Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)

Tildrakizumab-asmn (Ilumya®)

Multiple Surgery Payment Reduction

Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors

Evaluation and Management (E&M) of Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS)